$オンターナル セラピューティクス(ONCT.US)$ Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Dr. Smith's advisory role will help shape the clinical strategy for ONCT-534. Her expectation is that the drug could deal with escape mechanisms of a specific prostate cancer, boosting its prospective efficiency and market validity.
オンターナル セラピューティクスに関するコメント
Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
5分前、午前9時（EDT）
GLOBENEWSWIREを通じて
@OBIfromMEM
まだコメントはありません